Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 6, 2011

Unilabs to Offer Companion Diagnostic Services for Biogen Idec’s Tysabri

  • Biogen Idec has selected Unilabs to provide a companion diagnostic anti-JCV antibody assay test, called Stratify-JCV. The presence of anti-JCV antibodies is part of a three-factor risk stratification algorithm, along with prior immunosuppressant use and treatment duration, used to calculate the risk of Tysabri-treated patients developing progressive multifocal leukoencephalopathy (PML).

    The test is a two-step ELISA assay used to detect anti-JCV antibodies. To support customers, ordering needs, and volume of samples, Unilabs and Biogen Idec have also developed a closed web interface. This will allow neurologists to order sampling and shipping materials, register courier sample pick- up details, and request language and format of analytical reports. Also, neurologists can seek sampling, shipping, and medical support in five languages through a multilingual call center.

    The project is centralized to and managed by Unilabs in Copenhagen. “Unilabs is an independent commercial laboratory with a very high reputation, a strong European footprint, and excellent international skills, competences, and agility,” comments Natascha Schill, Biogen Idec.

    Unilabs says that it operates in over 100 laboratories and 30 radiology units in Europe. It serves hospitals, outpatients clinics, GPs, occupational health units, insurance companies, drug development companies, and CROs.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »